In a survey conducted by IPSOS on behalf of Enzymatica in 2019, ColdZyme was evaluated by parents of 50 children aged 4 to 17 years. A majority of the parents felt that common colds have a strong or very strong effect on the quality of life of their children. The survey results showed that the majority of the children used ColdZyme when they experienced the first common cold symptoms.
According to the parents, a majority of the younger children (ages 4 to 12 years) experienced fewer days with common cold symptoms and these symptoms were milder when using ColdZyme. About one third responded that ColdZyme had protected their children (both younger and older children) from common colds. Most of the parents felt that the instructions for using ColdZyme are easy to read and understand, and they would recommend ColdZyme to other parents for their children.
The evaluation also shows that reporting of side effects is very low. Among younger children, some form of side effect was reported in 8%. No side effects were reported among teens aged 13-17 years.
“The survey shows that the participating parents are satisfied with the efficacy of ColdZyme and that the product is well tolerated – which is in line with the results from similar studies,” says Fredrik Lindberg, CEO of Enzymatica.
Do you believe that your child experienced milder symptoms when using ColdZyme, compared with colds when ColdZyme was not used?
FOR MORE INFORMATION PLEASE CONTACT:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email: firstname.lastname@example.org
Carl-Johan Wachtmeister, Head of Corporate Communications, Enzymatica AB
Tel: +46 (0)701-88 50 21 | Email: email@example.com
ABOUT ENZYMATICA AB
Enzymatica AB is a life science company that develops and sells health products mainly to treat diseases and symptoms in the ear, nose and throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device product ColdZyme®, a mouth spray for colds. The product has been launched in around ten markets. The strategy is to continue to grow by developing more health products, strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North Growth Market. For more information please visit: www.enzymatica.se and www.enzymatica.se/sv/section/media/pressmeddelanden
Enzymatica’s Certified Adviser is Erik Penser Bank. Tel: +46 (0)8-463 83 00 E-post: firstname.lastname@example.org